West Pharmaceutical Services, Inc.
NYSE:WSTMedical - Instruments & Supplies
+$5.04 today
- Market cap
- $28.14B
- Beta
- 1.18
- P/E (TTM)
- 43.6
- EPS (TTM)
- $7.54
- Dividend yield
- 0.26%
Volume 0.59M
Average 0.85M
WST Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
West Pharmaceutical Services, Inc.NYSE: WST
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue grows in line with its trailing trend
Q2 FY2026 cost of revenue of $543.1M rose 10.2% year over year, in line with the +9.9% change in trailing-twelve-month cost of revenue. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.
Context
- Cost of revenue amounted to 64.1% of revenue in FY2025, down 1.2 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10.2% holds above the trailing-twelve-month pace of +9.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.97B USD
- Year-over-year change
- +4.2%
- 4-year CAGR
- +4.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.97B | +4.2% |
| FY2024 | 2024-12-31 | 1.89B | +4.0% |
| FY2023 | 2023-12-31 | 1.82B | +4.1% |
| FY2022 | 2022-12-31 | 1.75B | +5.4% |
| FY2021 | 2021-12-31 | 1.66B | — |
Cost of Revenue vs competitors
How WST compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.9% is the 2nd highest of 5, against a peer median of +3.8%.
- Cost of revenue amounts to 63.2% of revenue for WST, versus a peer median of 66.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.82B USD | +19.4% | +7.2% | 71.7% | |
| LTM Jun 2026 | $2.1B USD | +9.9% | +4.1% | 63.2% | |
| LTM Jun 2026 | $1.35B USD | -11.4% | -3.8% | 62.4% | |
| LTM Jun 2026 | €865.62M EUR | +5.0% | +6.8% | 70.8% | |
| LTM Mar 2026 | $36.03M USD | +2.6% | +5.1% | 36.1% | |
| Peer median (excluding WST) | — | +3.8% | +6.0% | 66.6% | |
Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.83B | 2.89B | 2.95B | 2.89B | 3.07B |
| Cost of Revenue | 1.66B | 1.75B | 1.82B | 1.89B | 1.97B |
| Gross Profit | 1.17B | 1.14B | 1.13B | 1B | 1.1B |
| Gross Margin | 41.5% | 39.5% | 38.4% | 34.6% | 35.9% |
| Research & Development | 52.8M | 58.5M | 68.4M | 69.1M | 74.3M |
| Selling, General & Admin | 361.9M | 316.9M | 353.4M | 338.5M | 393.1M |
| Operating Expenses | 414.7M | 375.4M | 421.8M | 407.6M | 485.9M |
| Depreciation & Amortization | 122.3M | 120.6M | 137.3M | 155.4M | 171.4M |
| EBITDA | 879.7M | 808.1M | 844.1M | 743.8M | 770.6M |
| EBITDA Margin | 31.1% | 28.0% | 28.6% | 25.7% | 25.1% |
| Operating Income | 758.7M | 763.5M | 710.9M | 594.6M | 617.4M |
| Operating Margin | 26.8% | 26.5% | 24.1% | 20.6% | 20.1% |
| Interest Income | 1M | 5.1M | 28M | 19.6M | 17.7M |
| Interest Expense | 8.5M | 7.6M | 8.8M | 2.9M | 600K |
| Other Income / Expenses | 10.3M | (62.9M) | 4.8M | 5.6M | (2.1M) |
| Income Before Tax | 769M | 700.6M | 715.7M | 600.2M | 615.3M |
| Pre-Tax Margin | 27.2% | 24.3% | 24.3% | 20.7% | 20.0% |
| Income Tax Expense | 107.2M | 114.7M | 122.3M | 107.5M | 121.6M |
| Net Income | 661.8M | 585.9M | 593.4M | 492.7M | 493.7M |
| Net Margin | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| EPS (Basic) | 8.90 | 7.88 | 7.99 | 6.75 | 6.83 |
| EPS (Diluted) | 8.67 | 7.73 | 7.88 | 6.69 | 6.80 |
| Weighted Avg Shares | 74.4M | 74.4M | 74.3M | 73M | 72.3M |
| Weighted Avg Shares (Diluted) | 76.3M | 75.8M | 75.3M | 73.7M | 72.7M |
West Pharmaceutical Services, Inc.
NYSE:WST
Intrinsic Alpha fair value
Locked
Current Price
$404.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.